TABLE OF CONTENTS
1 INTRODUCTION (Page No. – 17)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 MARKET SCOPE
1.2.2 MARKETS COVERED
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY (Page No. – 20)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.3 MARKET SIZE ESTIMATION METHODOLOGY
2.1.4 REVENUE MAPPING-BASED MARKET ESTIMATION (APPROACH 1)
2.1.5 MARKET ESTIMATION USING PARENT MARKET SIZE (APPROACH 2)
2.2 MARKET DATA ESTIMATION AND TRIANGULATION
2.3 ASSUMPTIONS OF THE STUDY
3 EXECUTIVE SUMMARY (Page No. – 30)
4 PREMIUM INSIGHTS (Page No. – 34)
4.1 RISK-BASED MONITORING SOFTWARE: MARKET OVERVIEW
4.2 RISK-BASED MONITORING SOFTWARE MARKET SHARE, BY TYPE, 2020 VS. 2025
4.3 RISK-BASED MONITORING SOFTWARE MARKET SHARE, BY COMPONENT, 2020 VS. 2025
4.4 RISK-BASED MONITORING SOFTWARE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW (Page No. – 36)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Cost and time efficiency of RBM solutions
5.2.1.2 Rising number of clinical trials
5.2.1.3 Increasing government funding and grants to support clinical trials
5.2.2 RESTRAINTS
5.2.2.1 High implementation costs
5.2.3 OPPORTUNITIES
5.2.3.1 Increased outsourcing of clinical trial processes to CROs
5.2.4 CHALLENGES
5.2.4.1 Dearth of skilled professionals for operating RBM solutions
6 RISK-BASED MONITORING SOFTWARE MARKET, BY TYPE (Page No. – 40)
6.1 INTRODUCTION
6.2 ENTERPRISE RBM SOFTWARE
6.2.1 ENTERPRISE RBM SOFTWARE DOMINATES THE RBM SOFTWARE MARKET
6.3 SITE RBM SOFTWARE
6.3.1 SITE RBM SOFTWARE OFFERS IMPROVED TRIAL MANAGEMENT
7 RISK-BASED MONITORING SOFTWARE MARKET, BY COMPONENT (Page No. – 45)
7.1 INTRODUCTION
7.2 SOFTWARE
7.2.1 GROWING ADOPTION OF CLINICAL TRIAL MANAGEMENT SOLUTIONS TO SUPPORT MARKET GROWTH
7.3 SERVICES
7.3.1 NEED FOR CONTINUOUS UPGRADE OF RBM SOFTWARE PRODUCTS HAS INCREASED THE DEMAND FOR SERVICES
8 RISK-BASED MONITORING SOFTWARE MARKET, BY DELIVERY MODE (Page No. – 50)
8.1 INTRODUCTION
8.2 WEB-BASED (ON-DEMAND)
8.2.1 ADVANTAGES SUCH AS EASY ACCESS & REDUCTION IN COSTS TO SUPPORT MARKET GROWTH
8.3 LICENSED ENTERPRISE (ON-PREMISE)
8.3.1 ON-PREMISE MODELS MINIMIZE RISKS ASSOCIATED WITH DATA BREACHES AND EXTERNAL ATTACKS
8.4 CLOUD-BASED (SAAS)
8.4.1 INCREASING ADOPTION OF CLOUD-BASED SOLUTIONS TO DRIVE MARKET GROWTH
9 RISK-BASED MONITORING SOFTWARE MARKET, BY END USER (Page No. – 57)
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
9.2.1 INCREASED PHARMACEUTICAL R&D SPENDING TO DRIVE MARKET GROWTH
9.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)
9.3.1 INCREASING OUTSOURCING OF CLINICAL RESEARCH ACTIVITIES BY PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDICAL DEVICE COMPANIES TO DRIVE MARKET GROWTH
9.4 MEDICAL DEVICE COMPANIES
9.4.1 GOVERNMENT FUNDING TO SUPPORT MARKET GROWTH
9.5 OTHER END USERS
10 RISK-BASED MONITORING SOFTWARE MARKET, BY REGION (Page No. – 66)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.1.1 The US holds the largest share of the North American market
10.2.2 CANADA
10.2.2.1 Government funding to boost market growth
10.3 EUROPE
10.3.1 GERMANY
10.3.1.1 Initiatives to boost digital health to propel market growth
10.3.2 UK
10.3.2.1 Favorable R&D scenario in the country to boost the adoption of RBM software
10.3.3 FRANCE
10.3.3.1 Lack of sufficient funding to restrain market growth in France
10.3.4 ROE
10.4 APAC
10.4.1 CHINA
10.4.1.1 Increased pharmaceutical R&D spending to drive market growth
10.4.2 JAPAN
10.4.2.1 Stringent regulatory scenario in Japan to restrain market growth
10.4.3 INDIA
10.4.3.1 Favorable pharmaceutical R&D scenario to drive the adoption of RBM software
10.4.4 REST OF ASIA PACIFIC
10.5 REST OF THE WORLD
11 COMPETITIVE LANDSCAPE (Page No. – 96)
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS
11.3 COMPETITIVE LEADERSHIP MAPPING
11.3.1 VISIONARY LEADERS
11.3.2 INNOVATORS
11.3.3 DYNAMIC DIFFERENTIATORS
11.3.4 EMERGING COMPANIES
11.4 COMPETITIVE SCENARIO
11.4.1 PRODUCT LAUNCHES & ENHANCEMENTS
11.4.2 FUNDING
11.4.3 ACQUISITIONS
11.4.4 PARTNERSHIPS
11.4.5 COLLABORATIONS
12 COMPANY PROFILES (Page No. – 103)
12.1 ORACLE
12.2 MEDIDATA SOLUTIONS
12.3 PAREXEL (ACQUIRED BY PAMPLONA CAPITAL MANAGEMENT)
12.4 BIOCLINICA
12.5 BIO-OPTRONICS
12.6 IBM
12.7 DATATRAK
12.8 VEEVA SYSTEMS
12.9 DSG
12.10 MASTERCONTROL
12.11 ERT
12.12 FORTE RESEARCH SYSTEMS
12.13 MEDNET SOLUTIONS
12.14 ARISGLOBAL
12.15 ANJU SOFTWARE
12.16 AXISIT
12.17 TECHSOL CORPORATION
12.18 OPENCLINICA
12.19 CRF HEALTH
12.20 COVANCE INC.